AACC 28TH INTERNATIONAL CPOCT SYMPOSIUM

Meeting Evolving Patient Needs Using Point-of-Care Testing

SEPTEMBER 21-23, 2022 | DOUBLETREE BY HILTON MONTREAL | MONTREAL, QC, CANADA

This activity is developed in partnership with the Canadian Society of Clinical Chemists and under the auspices of the International Federation of Clinical Chemistry and Laboratory Medicine.
**WEDNESDAY, SEPTEMBER 21, 2022**

5:30 – 7:00 p.m. Opening Network Reception  
Soprano

**THURSDAY, SEPTEMBER 22, 2022**

REGISTRATION AND BREAKFAST  
7:00 – 9:00 a.m. Registration outside Grand Salon  
Breakfast served in Soprano.

WELCOME AND KEYNOTE  
All main sessions will take place in Grand Salon.  
Exhibitors and meals will be located in Soprano.  
Posters will be on display in the Soprano Foyer.

8:30 – 8:35 a.m. Conference Welcome  
James H. Nichols, PhD, DABCC, FAACC (Planning Committee Chair)

8:35 – 9:35 a.m. COVID-19 Catalyzed Changes in STI Testing: Innovation and Access  
Yuka Manabe, MD, FIDSA, FRCP, Johns Hopkins Center for Global Health

SESSION 1: LESSONS OF THE COVID-19 PANDEMIC  
COVID-19 has challenged the delivery of POCT through the need for rapid method validation, on-demand training, makeshift testing locations and supply chain limitations. This session highlights novel approaches adopted by clinical laboratories, in vitro diagnostics companies, and others to address these challenges. Key learnings for future pandemics and for POCT in general are also discussed.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 9:35 – 9:40 a.m. | Moderator Introduction  
Allison Venner, PhD, FCACB, Alberta Precision Laboratories |
| 9:40 – 10:10 a.m. | Validation of Rapid COVID-19 Testing and On-Demand Training  
Antoine Corbeil, MD, FRCPC, Public Health Ontario |
| 10:10 – 10:40 a.m. | Global Viral Outbreaks & Public Health Emergencies In The Precision  
Medicine Era: How Far Has Healthcare Come In A Century?  
William G. Morice, II, MD, PhD, Mayo Clinic |
| 10:40 – 11:10 a.m. | Progress and Challenges of Point-of-Care Testing COVID-19  
from a Clinical Laboratory Perspective  
Allison Venner, PhD, FCACB, Alberta Precision Laboratories |
| 11:10 – 11:25 a.m. | Panel Discussion |
| 11:25 – 11:40 a.m. | Networking and Exhibitor Break (Soprano) |
## ORAL POSTER PRESENTATIONS

Oral poster presentations are delivered by the primary author of top-scored poster abstract submissions. Each oral poster presentation includes a presentation and Q&A period.

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40 – 11:55 a.m.</td>
<td>SARS-CoV-2 Result Positivity Rates Tracked Over Time in Symptomatic and Asymptomatic Individuals Tested with Molecular and Rapid Antigen Testing Methods</td>
<td>Raed Sulaiman, MD, Avera McKennan Hospital and University Health Center, Sioux Falls, SD</td>
<td></td>
</tr>
<tr>
<td>11:55 a.m. – 12:10 p.m.</td>
<td>Diagnostic Performance of Regulatory Approved Rapid Antigen Point-of-Care Tests in the Omicron BA.4/BA.5 Era in South Africa</td>
<td>Vidya Keshav, PhD, Wits Diagnostic Innovation Hub, University of the Witwatersrand, Johannesburg (South Africa)</td>
<td></td>
</tr>
<tr>
<td>12:10 – 12:25 p.m.</td>
<td>Impact of a Point-of-Care Test for Chlamydia Trachomatis (CT), Neisseria Gonorrhoeae (NG), and Trichomonas Vaginalis (TV) On Patient Care in an Urgent Care Clinic</td>
<td>Teresa Abraham, PhD, Visby Medical, San Jose, CA</td>
<td></td>
</tr>
<tr>
<td>12:25 – 1:25 p.m.</td>
<td>Lunch and Visit Exhibitors (Soprano)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## SESSION 2: DELIVERING HEALTHCARE IN NEW WAYS

As healthcare expands into the community, POCT is being incorporated into care pathways in novel ways in order to bring laboratory testing closer to the patient. This session explores the growing use of POCT in emergency services at festivals and events, in the care of underserved populations, and in other community-based health programs.

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:25 – 1:30 p.m.</td>
<td>Moderator Introduction</td>
<td>Anna Fuezery, PhD, DABCC, FCACB, Alberta Precision Laboratories</td>
<td></td>
</tr>
<tr>
<td>1:30 – 2:00 p.m.</td>
<td>Point-of-Care Testing to Support Street Medicine</td>
<td>Allison Chambliss, PhD, DABCC, University of Southern California</td>
<td></td>
</tr>
<tr>
<td>2:00 – 2:30 p.m.</td>
<td>Community Paramedicine and Point-of-Care Testing: Keeping Patients at Home Where They Belong</td>
<td>Anna Fuezery, PhD, DABCC, FCACB, Alberta Precision Laboratories</td>
<td></td>
</tr>
<tr>
<td>2:30 – 3:00 p.m.</td>
<td>Point-of-Care Testing Moving into the Community</td>
<td>Morgan L. Hutchinson, MD, Thomas Jefferson University Hospital</td>
<td></td>
</tr>
<tr>
<td>3:00 – 3:15 p.m.</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:15 – 3:30 p.m.</td>
<td>Networking and Exhibitor Break (Soprano)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ORAL POSTER PRESENTATIONS

Oral poster presentations are delivered by the primary author of top-scored poster abstract submissions. Each oral poster presentation includes a presentation and Q&A period.

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 3:30 – 3:45 p.m.| Verification Studies of New Point-of-Care Testing CBC Analyzer (Sight OLO) for Use in Rural and Remote Health Centers in the Province of Newfoundland and Labrador, Canada  
Vinita Thakur, PhD, Department of Laboratory Medicine, Health Sciences Center, Eastern health Authority and Memorial University, St John’s, NL (Canada) |
| 3:45 – 4:00 p.m.| Procalcitonin as a Predictor of Early Sepsis in Cardiovascular Surgery with Cardiopulmonary Bypass  
Eilysh Hildebrand, Response Biomedical Corp., Vancouver, BC (Canada) |
| 4:00 – 4:15 p.m.| Evaluation of the Rapid Quidel Sofia 2 Lyme Immunoassay as a First-Tier Test in a Two-Tier Testing Algorithm for Lyme Disease  
Kent Lewandrowski, MD, Massachusetts general Hospital, Boston, MA |

RECEPTION AND POSTER VIEWING

Posters will be on display in the Soprano Foyer.

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:15 – 5:45 p.m.</td>
<td>Networking and Poster Viewing Reception</td>
</tr>
</tbody>
</table>

EVENING SOCIAL EVENT: OLD MONTREAL GHOST WALKING TOUR

The evening social event is an optional activity that is available for an additional cost of $18 USD plus applicable fees and taxes. Please visit the registration desk outside Grand Salon for details on ticketing if you have not already registered.

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 – 9:30 p.m.</td>
<td>Tour departs from Place Royale at 8:00 p.m.</td>
</tr>
</tbody>
</table>

Old Montreal Ghost Walking Tour

Hosted by Phantom Montreal Tours.

Please note that the Old Montréal Ghost Tour is a ticketed event that is separate from meeting registration. Please also note that tickets for the Old Montréal Ghost Tour are no longer available for purchase.

For individuals that have previously purchased a ticket for the Old Montréal Ghost Tour, please note that the tour will depart from Place Royale, Montreal, QC, Canada at 8:00 p.m. Place Royale is approximately a 15-minute walk from the conference hotel.
FRIDAY, SEPTEMBER 23, 2022

REGISTRATION AND BREAKFAST
8:00 – 9:00 a.m. Registration outside Salon Opera
Breakfast served in Soprano.

WELCOME
All main sessions will take place in Grand Salon.

INDUSTRY VIEWPOINT
8:35 – 9:00 a.m. Evolution of Diabetes Management in Long Term Care in Canada:
Introducing Connected Point-of-Care Testing for Improved Resource Optimization - Lessons Learned
Lisa Vaughan, RN, BScN, LTCM, IIWCC, RAI-C
Director of Professional Practice
Caressant Care Nursing and Retirement Homes Ltd.
Sponsored by Roche Diagnostics

9:00 – 9:25 a.m. Ultra-Fast Quantitative Detection of Neutralizing Activity against
Multiple SARS-CoV-2 Variants
Alexandra Perebikovsky, PhD
VP, Immunochemistry
Autonomous Medical Devices Inc. (AMDI)
Sponsored by Autonomous Medical Devices Inc.
SESSION 3: PATIENT DRIVEN CARE IN A DATA DRIVEN WORLD

Patients are taking a greater role in managing their own health with the assistance of data provided by mobile watches, monitoring devices and direct-to-consumer testing. This session explores approaches for securely and confidentially sharing this data with a patient’s medical team, as well as controversies surrounding the integration of this data into the overall patient care pathway. The potential role of social media in the patient care pathway will also be discussed.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:35 – 9:40 a.m.</td>
<td>Moderator Introduction</td>
</tr>
<tr>
<td></td>
<td>Julie Shaw PhD, FCACB, University of Ottawa</td>
</tr>
<tr>
<td>9:40 – 10:05 a.m.</td>
<td>Future of Point-of-Care Testing: What’s Next for Devices, Data, and Areas to Expect Expansion</td>
</tr>
<tr>
<td></td>
<td>Ping Wang, PhD, DABCC, FAACC, Hospital of the University of Pennsylvania</td>
</tr>
<tr>
<td></td>
<td>Timothy S. Bailey, MD, FACE, CPI, Advanced Metabolic Care + Research</td>
</tr>
<tr>
<td>10:30 – 10:55 a.m.</td>
<td>Choosing Wisely Campaign</td>
</tr>
<tr>
<td></td>
<td>Lee Hilborne, MD, MPH, DLM(ASCP), University of California-Los Angeles</td>
</tr>
<tr>
<td>10:55 – 11:25 a.m.</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>11:25 – 11:40 a.m.</td>
<td>Networking and Exhibitor Break (Soprano)</td>
</tr>
</tbody>
</table>

ORAL POSTER PRESENTATIONS

Oral poster presentations are delivered by the primary author of top-scored poster abstract submissions. Each oral poster presentation includes a presentation and Q&A period.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40 – 11:55 a.m.</td>
<td>Quality Control, Cost Efficiency, and Improving Turnaround Time Using Individualized Quality Control Program in Point-of-Care Testing and Main Laboratory Setup</td>
</tr>
<tr>
<td></td>
<td>Muhammad Durrani, SBH, Bronx, NY</td>
</tr>
<tr>
<td>11:55 a.m. – 12:10 p.m</td>
<td>Evidence Based Approach to Implementing Point-of-Care Testing Methods and Practices in the Philippines</td>
</tr>
<tr>
<td></td>
<td>Merlito De Torres, Sidra Medicine, Doha (Qatar)</td>
</tr>
<tr>
<td>12:10 – 12:25 p.m.</td>
<td>Implementation of a Standardized Communication and Process for Preventing Loss of Glucose Meters and Patient Results</td>
</tr>
<tr>
<td></td>
<td>Shivani Sharma, Trillium Health Partners, Mississauga, ON (Canada)</td>
</tr>
<tr>
<td>12:25 – 1:25 p.m.</td>
<td>Lunch and Visit Exhibitors (Soprano)</td>
</tr>
</tbody>
</table>
SESSION 4: EVOLVING CLINICAL NEEDS FOR POINT-OF-CARE TESTING

The complexity of POCT is evolving. Laboratories are receiving an increasing number of requests for in-hospital use of continuous glucose monitors, for rapid fentanyl testing availability in emergency rooms, and for other novel POCT applications. This session highlights some of the challenges associated with these novel applications, and explores work being done by clinical laboratories, in vitro diagnostics companies, and others to address the challenges.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
</table>
| 1:25 – 1:30 p.m. | Moderator Introduction  
Brad S. Karon, MD, PhD, FAACC, Mayo Clinic                                    |
| 1:25 – 1:30 p.m. | Opportunities for Point-of-Care Testing in Patient-Driven Healthcare  
James H. Nichols, PhD, DABCC, FAACC, Vanderbilt University Medical Center     |
| 2:00 – 3:00 p.m. | Point-of-Care Drug Testing the Limitations and Benefits:  
A Point/Counterpoint Presentation  
Sara Love, PhD, DABCC, Siemens Healthineers  
David Marcovitz, MD, Vanderbilt Psychiatric Hospital |
| 3:00 – 3:15 p.m. | Panel Discussion                                                               |
| 3:15 – 3:45 p.m. | Networking and Exhibitor Break (Soprano)                                       |

CLOSING KEYNOTE

3:45 – 4:45 p.m. Direct to Consumer Testing and Future of Point-of-Care Testing  
Home Marketing  
Dina Greene, PhD, DABCC, LetsGetChecked

4:45 – 5:00 p.m. Closing Remarks  
James H. Nichols, PhD, DABCC, FAACC (Committee Chair)
PROGRAM FACULTY
PLANNING COMMITTEE

James Nichols, PhD, DABCC, FAACC (Chair)
Professor of Pathology, Microbiology and Immunology and Medical Director of Clinical Chemistry and Point of Care Testing
Vanderbilt University School of Medicine
Nashville, TN

Charbel Abou-Diwan, PhD, DABCC, FAACC
Medical Affairs / Medical Officer Siemens Healthineers
Walpole, MA

Anna Fuezery, PhD, DABCC, FCACB
North Sector POCT Medical Lead
Alberta Precision Laboratories
Edmonton, AB (Canada)

Brad Karon, MD, PhD, FAACC
Dean of Mayo Clinic School of Health Sciences Professor of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, MN

Julie Shaw, PhD, FCACB
Head, Division of Biochemistry and Director for POCT
Eastern Ontario Regional Laboratories Association / The Ottawa Hospital / The University of Ottawa Ottawa, ON (Canada)

Allison Venner, PhD, FCACB
Clinical Biochemist
Alberta Precision Laboratories
Calgary, AB (Canada)
ADDITIONAL FACULTY PRESENTERS

Timothy S. Bailey, MD, FACE, CPI
Founder and CEO
Advanced Metabolic Care + Research
Escondido, CA

Allison Chambliss, PhD, DABCC
Associate Professor of Clinical Pathology
University of Southern California
Los Angeles, CA

Antoine Corbeil, MD, FRCPC
Medical Microbiologist, Microbiology and Laboratory Science
Public Health of Ontario
Toronto, ON (Canada)

Dina Greene, PhD, DABCC
Associate Laboratory Director
LetsGetCheckedBurien, WA

Lee Hilborne, MD, MPH, DLM(ASCP)
Professor and Medical Director, University of California-Los Angeles
Senior Medical Director, Quest Diagnostics
Los Angeles, CA

Morgan L. Hutchinson, MD
Emergency Physician, Director of Education
Health Design Lab, Assistant Medical Director
Thomas Jefferson University Hospital
Philadelphia, PA

Sara Love, PhD, DABCC
Medical Officer
Siemens Healthineers
Newark, DE

Yuka Manabe, MD, FIDSA, FRCP
Associate Director of Global Health Research and Innovation
Professor of Medicine
Johns Hopkins Center for Global Health
Baltimore, MD

David Marcovitz, MD
Director, Division of Addiction Psychiatry
Vanderbilt University Medical Center/Vanderbilt Psychiatric Hospital
Nashville, TN

William G. Morice, II, MD, PhD
Mayo Clinic
Rochester, MN

Ping Wang, PhD, DABCC, FAACC
Director of Clinical Chemistry
Hospital of the University of Pennsylvania
Philadelphia, PA

GUEST PRESENTERS

Lisa Vaughan, RN, BScN, LTCM, IIWCC, RAI-C
Director of Professional Practice
Caressant Care Nursing and Retirement Homes Ltd.

Alexandra Perebikovsky, PhD
VP Immunochemistry Autonomous Medical Devices Inc.
**LEARNING OBJECTIVES**

Upon completion of this educational activity, learners will be better able to:

- Discover how POCT is evolving to meet changing clinical needs.
- Realize the growing use of POCT in the community.
- Explore novel ways that POCT data is personalizing healthcare.
- Identify the challenges and lessons learned from the COVID-19 pandemic.

**TARGET AUDIENCE**

This symposium is designed to meet the needs of laboratory professionals overseeing and/or carrying out point-of-care testing, clinical laboratory physicians, supervisors, managers, regulatory personnel, and other laboratory professionals interested in advances in point-of-care testing.

**DISCLOSURES AND STATEMENT OF INDEPENDENCE**

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to learners any financial relationship(s) that have occurred within the last 24 months with any ineligible company. There is no minimum financial threshold. An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are defined by remuneration in any amount from the ineligible company in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. All disclosures are reviewed and resolved or managed all identified conflicts of interest, as applicable.

The following planning committee members and faculty disclosed financial relationships:

- Charbel Abou-Diwan received salary from Siemens Healthineers.
- Timothy Bailey: (1) received grant support from Abbott Diabetes, Abbott Rapid Diagnostics, Biolinq, Capillary Biomedical, Dexcom, Eli Lilly, Kowa, LifePlus, Livongo, Mannkind, Medtronic, Novo Nordisk, PKVitality, REMD, Sanofi, Sanvita, Senseonics, Viacyte, vTv Therapeutics, and Zealand Pharma; (2) served on an advisory board and/or committee for Abbott, CeQur, Lifescan, Mannkind, Medtronic, Novo, and Sanofi; and (3) served as a speaker for Mannkind, Medtronic, and Sanofi.
- Allison Chambliss: (1) received a consultant fee from Roche Diagnostics and (2) served as a speaker for Cardinal Health.
- Anna Fuezery served on an advisory board and/or committee for Quidel Canadian Advisory Board member.
- Lee Hilborne: (1) received grant support from Quest Diagnostics; (2) received salary from Quest Diagnostics; and (3) has stocks and/or bonds from Quest Diagnostics.
- Sara Love received salary from Siemens Healthineers.
- Yukari Manabe received grant support from Hologic, Cepheid, Roche, ChemBio, Becton Dickinson, and miDiagnostics.
- David Marcovitz has equity with Better Life Partners LLC and Silver Pines LLC.
MEETING EVOLVING PATIENT NEEDS USING POINT-OF-CARE TESTING

PROGRAM OVERVIEW

- James Nichols: (1) has received grant support from Abbott Diagnostics, IL, iAssay, Essenlix, and Roche; (2) received a consultant fee from Abbott; (3) served on an advisory board and/or committee for IL Scientific Advisory Committee, Abbott Alere Advisory Board; and (4) served as a speaker for Abbott, Bio-Rad, and IL.
- Julie Shaw has served on an advisory board and/or committee for Abbott POCT, HLS Therapeutics, and Roche POCT.
- Ping Wang: (1) receive grant support from Instanosis; (2) received a consultant fee from BioRad; (3) served on an advisory board and/or committee for Truvian; and (4) has stocks and/or bonds from Instanosis.

The following faculty disclosed no financial relationships:
- Antoine Corbeil
- Dina Greene
- Morgan Hutchinson
- Brad Karon
- William Morice
- Allison Venner

CONTENT VALIDITY

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

SPONSORSHIP STATEMENT

This activity is sponsored by Abbott Rapid Diagnostics Informatics, Inc., Autonomous Medical Devices Incorporated (AMDI), BD, Inter-Medico, LumiraDx, Nova Biomedical, Response Biomedical, Roche Diagnostics, Siemens Healthineers, TELCOR, Visby Medical, and Werfen.

ACCREDITATION STATEMENT

The American Association for Clinical Chemistry, Inc. (AACC) provides an accreditation program, Advances in Clinical Chemistry Education and New Technology (ACCENT®). AACC’s ACCENT® program is to assure and advance quality learning for clinical laboratory professionals that drives improvements in patient care. This education activity is accredited for 11.0 ACCENT credits.

Participants of this activity will be sent instructions by email at the end of the activity from AACC Education to complete a brief evaluation and claim ACCENT continuing education credit. Please contact education@aacc.org with any questions.

SUCCESSFUL COMPLETION STATEMENT

Verification of Participation certificates are provided to registered participants based on successful completion of the activity, in its entirety, and the activity evaluation. Please contact education@aacc.org with any questions.
Scientific Posters

DISPLAYS START IN SOPRANO FOYER:  
Wednesday, September 21 | 5:30 p.m.

DISPLAYS CONCLUDE:  
Friday, September 23 | 5:00 p.m.

1 | Real-Time, Multiplexed CRISPR-Cas Diagnostics to Enable Point-of-Need In Vitro Diagnostic Testing  
Elizabeth Fiore, Sherlock Biosciences, Inc., Watertown, MA (United States)

2 | Selection of DNA Aptamers for Point-of-Care Detection  
Juewen Liu, University of Waterloo, Waterloo, ON (Canada)

3 | Verification Studies of New Point-of-Care Testing CBC Analyzer (Sight OLO) for Use in Rural and Remote Health Centers in the Province of Newfoundland and Labrador, Canada  
Vinita Thakur, Department of Laboratory Medicine, Health Sciences Center, Eastern health Authority and Memorial University, St John’s, NL (Canada)

Brenda Torres, CanaryQ, Mountain View, CA (United State)

5 | Filtering Fingerstick-Blood Can Help Reduce the Overestimate of Glucose Levels in Anemic Samples  
Brenda Torres, CanaryQ, Mountain View, CA (United States)

6 | Glucose Readings from Filtered Fingerstick Plasma Remain Constant Across 4 Hours at Room Temperature: Ideal for Oral Glucose Tolerance Testing  
Brenda Torres, CanaryQ, Mountain View, CA (United States)

7 | Innovative Artificial Intelligence Driven Antibody Test for Point-of-Care  
Rian Wendling, NanoSpot.ai, Inc., Salt Lake City, UT (United States)

8 | Establishing Quality Indicators for Point-of-Care Testing  
Julie Shaw, Eastern Ontario Regional Laboratories Association/University of Ottawa, Ottawa, ON (Canada)

9 | SARS-CoV-2 Result Positivity Rates Tracked Over Time in Symptomatic and Asymptomatic Individuals Tested with Molecular and Rapid Antigen Testing Methods  
Raed Sulaiman, Avera McKennan Hospital and University Health Center, Sioux Falls, SD (United States)

10 | Analytical Performance of the Visby Sexual Health Point-of-Care Test for Sexually Transmitted Infections  
Leslie Donato, Mayo Clinic, Rochester, MN (United States)

11 | Point-of-Care Testing in Philippine Ground Ambulances, a Sea Ambulance, and Emergency Rescue Vehicles  
Anna Fuezery, Alberta Precision Laboratories, Edmonton, AB (Canada)

12 | Analytical Verification and Clinical Deployment of the Nova StatStrip Xpress Glucose Meter in Ground Ambulances  
Anna Fuezery, Alberta Precision Laboratories, Edmonton, AB (Canada)
13 | Analytical Performance Verification and Quality Assurance Program Changes for Point-of-Care ROTEM Thromboelastometry in Cardiovascular Surgery  
Anna Fuezery, Alberta Precision Laboratories, Edmonton, AB (Canada)

14 | A Study of Peritoneal Lactate Levels in Emergency Abdominal Pain Evaluation: Role of Point-of-Care Testing in Emergency Settings  
Shilpa Hasija, ESIC-PGIMSR, Delhi, Delhi (India)

15 | Diagnostic performance of regulatory approved rapid antigen point-of-care tests in the Omicron BA.4/BA.5 era in South Africa  
Vidya Keshav, Wits Diagnostic Innovation Hub, University of the Witwatersrand, Johannesburg (South Africa)

16 | Impact of a Point-of-Care Test for Chlamydia Trachomatis (CT), Neisseria Gonorrhoeae (NG), and Trichomonas Vaginalis (TV) On Patient Care in an Urgent Care Clinic  
Teresa Abraham, Visby Medical, San Jose, CA (United States)

17 | Nanofluidic Technology Enables Rapid Quantification of Pancreatic Stone Protein as an Early Biomarker of Sepsis: Method Comparison of the abioSCOPE In-Vitro Diagnostic Device  
Romy Benninga, Abionic, Cambridge, MA (United States)

18 | Validation of a Novel 2-Minute IVD COVID-19 Rapid Antigen Test on the AbioSCOPE® Device for Detection of SARS-CoV-2 Through Nanofluidics  
Romy Benninga, Abionic SA, Epalinges (Switzerland)

19 | Performance Evaluation of Nova Century Scientific One Step Multi-Line Screen Test Device for Measurement of Drugs of Abuse in the Urine  
Yury Butorin, Alberta Precision Laboratories, Red Deer, AB (Canada)

20 | Procalcitonin as a Predictor of Early Sepsis in Cardiovascular Surgery with Cardiopulmonary Bypass  
Eilysh Hildebrand, Response Biomedical Corp., Vancouver, BC (Canada)

21 | Analytical Sensitivity of ACON and LumiraDx SARS-CoV-2 Rapid Antigen Tests for Detection of Presumed Omicron Variant  
Brad Karon, Mayo Clinic, Rochester, MN (United States)

22 | ProSpectral™: Fast, Accurate, and High-Throughput Screening of COVID-19 Infections  
Matt Keener, Pattern Computer, Inc., Friday Harbor, WA (United States)

23 | Evaluation of the Rapid Quidel Sofia 2 Lyme Immunoassay as a First-Tier Test in a Two-Tier Testing Algorithm for Lyme Disease  
Kent Lewandrowski, Massachusetts general Hospital, Boston, MA (United States)

24 | Clinical Evaluation of a New, Near-Patient Testing (NPT) IL-6 Assay to Identify the Disease Severity in COVID-19 Patients  
Madhusudhanan Narasimhan, UT Southwestern Medical Center, Dallas, TX (United States)
25 | Contamination of Glucose Test Strips with Hand Sanitizer or Cleaning Solution Leads to Erroneously Low Glucose Results
Heather Paul, Alberta Precision Laboratories/University of Calgary, Calgary, AB (Canada)

26 | A Rapid, Cell-Free Test for the Quantitative Measurement of Neutralizing Antibody Activity Against SARS-CoV-2 and Its Variants
Alexandra Perebikovsky, Autonomous Medical Devices Inc, Santa Ana, CA (United States)

27 | An Optimal Extraction Method for STI Organisms for Microfluidic Application
Cheryl Sesler, Eurofins ARCA Technology, Inc., Huntsville, AL (United States)

28 | Point-of-Care 13 C-Urea Breath Test Implementation in the Endoscopy Unit at King Faisal Specialist Hospital and Research Centre
Mohamed Abdelsalam, King Faisal Specialist Hospital and Research Centre, Riyadh (Saudi Arabia)

29 | Evidence Based Approach to Implementing Point-of-Care Testing Methods and Practices in the Philippines
Merlito De Torres, Sidra Medicine, Doha (Qatar)

30 | Quality Control, Cost Efficiency, and Improving Turnaround Time Using Individualized Quality Control Program in Point-of-Care Testing and Main Laboratory Setup
Muhammad Durrani, SBH, Bronx, NY (United States)

31 | Prevalence of Hemolyzed Whole Blood Potassium Results in Acute Care Settings
James Nichols, Vanderbilt University Medical Center, Nashville, TN (United States)

32 | Implementation of a Standardized Communication and Process for Preventing Loss of Glucose Meters and Patient Results
Shivani Sharma, Trillium Health Partners, Mississauga, ON (Canada)

33 | Comparison of the eGFR Calculated Using Whole Blood Creatinine Measured with Radiometer ABL 827 FLEX with the eGFR Calculated Using Plasma Creatinine
Lu Song, University of California, Los Angeles, Los Angeles, CA (United States)

34 | Potential Application of Point-of-Care Glucose and Beta-Hydroxybutyrate Measurements for Suspected Diabetic Ketoacidosis on Decedent Blood and Vitreous Humor in Forensic Autopsy
Paul Yip, Sunnybrook Hospital and University of Toronto, Toronto, ON (Canada)
Autonomous Medical Devices Incorporated (AMDI) is an early-stage, California company focused on developing and manufacturing Autolabs and their associated test discs for human clinical diagnostics. Each of AMDI’s Autolabs are small, portable point-of-care diagnostics devices using breakthrough microfluidics, hardware, and data/cloud connectivity to deliver lab quality results in <15 minutes. AMDI has built a world class, multi-disciplinary team of engineers, scientist, clinicians, and database experts and will launch its first Research Use Only (RUO) products in 2023 from its ISO 13485 certified 110,000 square foot facility in Santa Ana, CA.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Abbott Rapid Diagnostics Informatics, Inc. (ARDx Informatics) vision is to enable our customers with the most comprehensive POC connectivity experience. Our mission is to provide solutions and services are designed to help our customers with the best possible connectivity experience while expanding the access to the care continuum. We do this by providing information, resources and security with abundant depth driven by our customer focused innovation and best in class quality to manage the POC program using our RALS™ and AegisPOC connectivity systems.

Siemens Healthineers Point of Care portfolio is designed to provide immediate, convenient, and easy-to-use diagnostic testing solutions. Join us at the 28th AACC International CPOCT Symposium in Montreal to learn how to lower costs and improve outcomes with HbA1c testing and view our comprehensive urinalysis portfolio that uses the same reagent strip technology, standardizing testing at every location. Also showcased this year is our critical care testing portfolio, which reduces complexity, improves operational efficiency, and provides you with flexible, long-term solutions. Our suite of customizable analyzers ranges from handheld to benchtop systems and delivers results that are comparable, no matter where the testing takes place.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, and equip surgical and interventional procedures. BD offers rapid diagnostic testing solutions with SARS-CoV-2, Flu A+B, RSV (respiratory syncytial virus), and Group A Strep assays.

At Inter Medico we offer more than just products. We provide Canada-wide bilingual support excellence through our Account Managers, Technical Specialists, Service Engineers, and an operational team that can deliver products next-day from coast-to-coast. We offer breakthrough CPOCT technologies for both chemistry and hematology that can positively impact the laboratories clinical, operational, and financial decisions. Over the past 40 years, we have developed long standing relationships across Canada, and we are recognized for our commitment and dedication to our customers and vendors alike.

LumiraDx is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, the company manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. The company has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.
**Nova Biomedical**
novabiomedical.com

Nova Biomedical is the world technology leader in the development of fast, whole blood analyzers to support the care of hospitalized and critically ill patients. Nova analyzers offer the most extensive stat test menus and deliver results in the shortest time at the lowest costs. Nova also provides handheld meter-and-strip based measuring systems for glucose, ketone, lactate, and creatinine point-of-care testing. Whether testing is performed in the central laboratory or in emergency, surgical, critical, or respiratory care areas, Nova analyzers can help to improve patient outcomes while reducing the cost of care.

**Response Biomedical**
responsebio.com

Response Biomedical Corp. develops, manufactures, and markets the RAMP system, a rapid diagnostics platform that delivers lab quality performance for efficient patient management in acute care settings. RAMP is a global leader in comprehensive acute care testing with a wide range of markers available including Troponin I, CK-MB, Myoglobin, NT-proBNP, D-dimer, Procalcitonin and Total β-hCG. For effective and efficient patient care, RAMP tests aid in the diagnosis of Acute Myocardial Infarction, Heart Failure, Sepsis and Women’s Health.

**TELCOR**
telcor.com

TELCOR provides connectivity and data management to more POC device types and LIS/EMR systems than any provider in the industry. We are the only POC middleware vendor with no diagnostic or LIS company ownership allowing us to connect any manufacturer’s devices. With more than 8,700 device types at more than 2,500 hospitals and thousands of ambulatory sites connected to TELCOR QML®, facilities are able to collect results electronically thus saving time and improving data quality. By focusing on software, we are not distracted with selling devices or reagents. We positively provide the best solutions, support, and service in the industry.
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain. We are a worldwide leader in specialized diagnostics in the areas of Hemostasis, Acute Care Diagnostics and Autoimmunity. Our comprehensive and integrated Acute Care Diagnostics line is comprised of whole-blood testing systems to help clinicians and laboratorians achieve better patient outcomes, lower total cost of care, assure regulatory compliance and enhance operational efficiency in hospital Acute Care settings. From the CVOR and Cath Lab, to ICUs and EDs, our Acute Care Diagnostic solutions address today’s healthcare challenges. Key products include our GEM Premier blood gas systems, GEM Premier ChemSTAT and Avoximeter 1000E, as well as the whole-blood hemostasis family, featuring ROTEM, HemoChron and VerifyNow systems.